Pyrazoloacridine is an investigational nucleic acid binding agent that inhibits the activity of topoisomerases 1 and 2. Pyrazoloacridine was a phase II clinical study to determine the efficacy and toxicities of PZA in patients with metastatic breast cancer (MBC)Pyrazoloacridine appears to intercalate into DNA and inhibit RNA synthesis, DNA synthesis, and the activities of topoisomerases I and II, thereby causing cytotoxicity. References: Chen DS, Zhou YJ, Li YL, Yao CS, Wang XS. Combinatorial synthesis of pyrazoloquinoline and pyrazoloacridine derivatives with high regioselectivity. Comb Chem High Throughput Screen. 2013 Jun 28;16(7):550-61. PubMed PMID: 23410044.

纯度：≥98%

CAS：99009-20-8